Clinical trial
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence…
NCT00090285 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00090285 |
|---|---|
| Title | An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) |
| Official title | An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Condylomata Acuminata |
| Intervention type | Biological |
| Interventions | (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, Comparator: placebo (unspecified) |
| Enrollment | 4,065 |
| Start date | Sep 3, 2004 |
| Primary completion | Jul 31, 2009 |
| Completion | Apr 3, 2017 |
| First posted | Aug 27, 2004 |
| Last update posted | Aug 23, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: